The Business Research Company’s report on the Urticaria Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the urticaria market in recent years?
The increasing skin disease awareness and treatment is expected to boost the growth of the urticaria market going forward. Increasing pollution leads to more skin allergies and conditions, driving demand for awareness and advanced treatments. Urticaria contributes to skin disease awareness and treatment by showcasing immune system responses, driving research, enhancing diagnostics, and advancing targeted therapies. For instance, in February 2024, The Skin Cancer Foundation, a US-based nonprofit, reported that 1 in 5 Americans develop skin cancer by age 70, with over 2 deaths occurring every hour in the U.S. This highlights the urgent need for preventive measures, as having five or more sunburns doubles the risk of melanoma. Therefore, increasing skin disease awareness and treatment is driving the growth of the urticaria market.
Access Your Free Sample of the Global Urticaria Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23554&type=smp
What is the projected market size of the urticaria industry, and how is it expected to grow?
The urticaria market size has grown rapidly in recent years. It will grow from $4.03 billion in 2024 to $4.77 billion in 2025 at a compound annual growth rate (CAGR) of 18.2%. The growth in the historic period can be attributed to the increasing prevalence of allergies, rising awareness of skin disorders, rising advancements in immunology and biologics, growing demand for antihistamines, and improving diagnostic techniques.
The urticaria market size is expected to see rapid growth in the next few years. It will grow to $9.23 billion in 2029 at a compound annual growth rate (CAGR) of 18.0%. The growth in the forecast period can be attributed to rising cases of chronic urticaria, growing adoption of biologic therapies, increasing investments in dermatology research, expanding access to advanced allergy diagnostics, and increasing development of personalized medicine. Major trends in the forecast period include AI-powered diagnostic tools, the development of novel biologics, advancements in personalized immunotherapy, wearable skin monitoring devices, and telemedicine for allergy management.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23554&type=smp
Who are the key players driving competition in the urticaria market?
Major companies operating in the urticaria market are Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Incyte Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Ltd., Amneal Pharmaceuticals Inc, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Almirall S.A., Argenx SE, BioCryst Pharmaceuticals Inc., Pharvaris NV, Revolution Medicines Inc., Allakos.
Which emerging trends are set to transform the urticaria market landscape?
Major companies operating in the urticaria market are focusing on developing innovative solutions such as mast cell inhibitor antibodies to develop an advanced therapeutic solution for managing chronic spontaneous urticaria by targeting mast cell activation. A mast cell inhibitor antibody is a targeted monoclonal antibody that blocks the activation or degranulation of mast cells by inhibiting specific receptors or signaling pathways, thereby reducing allergic reactions, inflammation, and other mast cell-mediated disorders. For instance, in May 2024, Allakos Inc., a US-based biotechnology company, announced the initiation of a Phase 1 clinical trial for AK006, designed for the treatment of chronic spontaneous urticaria (CSU). This innovative therapy targets both IgE-dependent and IgE-independent mast cell activation pathways, offering the potential for broader efficacy in patients who are refractory to antihistamines or prior biologic treatments. By selectively inhibiting mast cell activity through the Siglec-6 receptor, AK006 aims to provide a more comprehensive and long-lasting solution for CSU management, marking a significant advancement in urticaria treatment and immunotherapy research.
Which key geographies are driving the growth of the urticaria market?
North America was the largest region in the urticaria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/urticaria-global-market-report
What are the key segments driving growth in the urticaria market?
The urticaria market covered in this report is segmented –
1) By Type: Acute Urticaria, Chronic Urticaria
2) By Drug Class: Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Urticaria: Allergic Urticaria, Infectious Urticaria, Drug-Induced Urticaria, Contact Urticaria
2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU)
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23554
How is the urticaria market defined, and what are its core characteristics?
Urticaria, commonly known as hives, is a skin condition characterized by red, itchy, and raised welts. It occurs due to an allergic reaction, stress, or unknown triggers, leading to histamine release. The condition can be acute (lasting less than six weeks) or chronic (persisting longer). Treatment includes antihistamines, avoiding triggers, and, in severe cases, corticosteroids or immunotherapy.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
